Applied Clinical Trials Online3d
SOUL Trial Shows Oral Semaglutide Significantly Reduces Cardiovascular Risk in Type 2 Diabetes
Phase III SOUL trial shows daily oral semaglutide lowers the risk of major adverse cardiovascular events in patients with ...
Top 3 Health Care Stocks That Are Set To Fly This Month
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Oncology Nursing News12d
Vepdegestrant Meets PFS End Point for Metastatic Breast Cancer Subtype
Vepdegestrant (ARV-471) yielded a statistically significant and clinically meaningful improvement in progression-free ...
Applied Clinical Trials Online13d
VERITAC-2 Trial Shows Vepdegestrant Significantly Improves Survival in ESR1-Mutant Breast Cancer
Phase III VERITAC-2 trial results show vepdegestrant significantly improved progression-free survivalcompared to fulvestrant ...
Stockhouse17d
Arvinas and Pfizer Announce Positive Topline Results from Phase 3 VERITAC-2 Clinical Trial
NEW HAVEN, Conn. and NEW YORK, March 11, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 VERITAC-2 clinical ...
PMLiVE19d
Pfizer/Arvinas’ vepdegestrant shows promise in phase 3 breast cancer study
The phase 3 VERITAC-2 trial has been evaluating the candidate against AstraZeneca’s endocrine therapy Faslodex (fulvestrant) in adults with oestrogen receptor (ER)-positive, human epidermal growth ...
Investing20d
Arvinas’s SWOT analysis: vepdegestrant potential drives stock outlook
The company is currently awaiting topline data from the Phase 3 VERITAC-2 trial, which is expected to be released in the first quarter of 2025. This trial is crucial for Arvinas, as it will provide ...